Patents Assigned to British Biotech Pharmaceutical Limited
-
Patent number: 7173053Abstract: Compounds of formula (I) are antibacterial or antiprotozoal agents for treatment of infections in humans and non-human mammals, wherein: Z represents a radical of formula —N(OH)CH(?O) or formula C(?O)NH(OH); R1 represents hydrogen, methyl or trifluromethyl, or except when Z is a radical of formula —N(OH)(?O), a hydroxy, halo or amino group; R2 represents a group R10—(X)n-(ALK)m— wherein R10, ALK, X, m and n are as defined in the specification; R3 represents hydrogen, (C1–C6) alkyl or phenyl(C1–C6)alkyl-; and R5 and R6 are as defined in the specification.Type: GrantFiled: November 8, 2001Date of Patent: February 6, 2007Assignee: British Biotech Pharmaceuticals LimitedInventors: Paul Raymond Beckett, Steven Launchbury, Gilles Pain, Lisa Marie Pratt
-
Patent number: 6908911Abstract: Selected compounds of formula (I) are antibacterial agents: formula (I) wherein R2 represents a substituted or unsubstituted C1-C6 alkyl, cycloalkyl (C1-C6 alkyl)- or aryl (C1-C6 alkyl)-group, and A represents a group of formula (IA), or (IB) wherein R4 represents the side chain of a natural or non-natural alpha amino acid, and R5 and R6 are each independently hydrogen or C1-C6 alkyl, heterocyclic or aryl (C1-C6 alkyl)-, R5 and R6 when taken together with the nitrogen atom to which they are attached from an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ringType: GrantFiled: August 10, 1999Date of Patent: June 21, 2005Assignee: British Biotech Pharmaceuticals LimitedInventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker, Stephen John Davies, Lisa Marie Pratt, Zoe Marie Spavold, Steven Launchbury
-
Patent number: 6846825Abstract: Compounds of formula (II) are antibacterial agents wherein Q represents a radical of the formula: —N(OH)CH(?O) or the formula: —C(?O)NH(OH); R1 represents hydrogen, C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of the formula: —N(OH)CH(?O), a hydroxy, C1-C6 alkoxy, C1-C4 alkenyloxy, amino, C1-C4 alkylamino, or di-(C1-C6 alkyl)amino group; R2 represents a substituted or unsubstituted C1-C6 alkyl, cycloalkyl(C1-C6 alkyl)- or aryl(C1-C6 alkyl)-group; and A represents a group of formula (IIA), or (IIB) wherein R4 represents the side chain of a natural or non-natural alpha amino acid, and R5 and R6 when taken together with the nitrogen atom to which they are attached form a saturated heterocyclic first ring of 5 to 7 atoms as specified in the description.Type: GrantFiled: August 10, 2000Date of Patent: January 25, 2005Assignee: British Biotech Pharmaceuticals LimitedInventors: Lisa Marie Pratt, Kenneth Noel Keavey, Gilles Denis Pain, Laurent Mounier
-
Patent number: 6441042Abstract: Compounds of formula (I) are antibacterials wherein: R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10—(X)n—(ALK)m— wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, —COOH, —CONH2, —COORA, —NHCORA, —CONHRA, —NHRA, —NRARB, or —CONRARB wherein RA and RB are independently a (C1-C6)alkyl group, and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages, X represents —NH—, —O— or —S—, and m and n are indepeType: GrantFiled: November 15, 2000Date of Patent: August 27, 2002Assignee: British Biotech Pharmaceuticals LimitedInventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker, Zoe Marie Spavold
-
Patent number: 6358987Abstract: A compound of formula (I) wherein X is —COOH or —CONHOH Y is a group of formula (ID) or (IE) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation.Type: GrantFiled: March 5, 2001Date of Patent: March 19, 2002Assignee: British Biotech Pharmaceuticals LimitedInventors: Raymond Paul Beckett, Fionna Mitchell Martin, Andrew Miller, Richard Simon Todd, Mark Whittaker
-
Patent number: 6310084Abstract: The present invention relates to therapeutically active hydroxamic acid, N-formyl-N-hydroxyamino and carboxylic acid derivatives, their preparation, and pharmaceutical compositions containing them. These compounds are useful in the inhibition of metalloproteases, such as stromelysin, gelatinase, matrilysin, and collagenase. These compounds are useful in the treatment of mammals having disease-states alleviated by the inhibition of such matrix metalloproteases.Type: GrantFiled: February 11, 2000Date of Patent: October 30, 2001Assignee: British Biotech Pharmaceuticals LimitedInventors: Raymond Paul Beckett, Fionna Mitchell Martin, Richard Simon Todd
-
Patent number: 6271262Abstract: A compound of formula (I) useful as metalloproteinase inhibitors.Type: GrantFiled: January 11, 2000Date of Patent: August 7, 2001Assignee: British Biotech Pharmaceuticals LimitedInventors: Raymond Paul Beckett, Fionna Mitchell Martin, Andrew Miller, Richard Simon Todd, Mark Whittaker
-
Patent number: 6258851Abstract: Compounds of formula (I), wherein A, B, X, R1, R2, R3, R4, R5, R6 are as defined in the specification, are matrix metalloproteinase inhibitors.Type: GrantFiled: October 8, 1999Date of Patent: July 10, 2001Assignee: British Biotech Pharmaceuticals LimitedInventors: Christopher David Floyd, Sanjay Ratilal Patel, Mark Whittaker
-
Patent number: 6169075Abstract: Compounds of formula 1 wherein R4 is an ester or thioester group, and R, R1, R2 and R3 are as defined in the specification are inhibitors of rapidly dividing tumour cells.Type: GrantFiled: September 8, 1997Date of Patent: January 2, 2001Assignee: British Biotech Pharmaceuticals LimitedInventors: Lindsey Ann Pearson, Andrew Paul Ayscough, Philip Huxley, Alan Hastings Drummond
-
Patent number: 6127427Abstract: Compounds of general formula (I) ##STR1## wherein X ia a --CO.sub.2 H, --NH(OH)CHO or --CONHOH group; R.sub.1 is a cylcoalkyl, cycloalkenyl or non-aromatic heterocyclic ring containing up to 3 heteroatoms, any of which may be (i) substituted by one ore more substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, halo, cyano (--CN), --CO.sub.2 H, --CO.sub.2 R, --CONH.sub.2, --CONHR, --CON(R).sub.2, --OH, --OR, oxo-, --SH, --SR, --NHCOR, and --NHCO.sub.2 R wherein R is C.sub.1 -C.sub.6 alkyl or benzyl and/or (ii) fused to a cycloalky or heterocyclic ring; and R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined in specification are matrix metalloproteinase inhibitors.Type: GrantFiled: May 22, 1998Date of Patent: October 3, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Fionna Mitchell Martin, Christopher Norman Lewis, Mark Whittaker
-
Patent number: 6124333Abstract: Therapeutically active hydroxamic acid derivatives, processes for their preparation, pharmaceutical compositions containing them, and the use of such compounds in medicine. The compounds are inhibitors of metalloproteinases involved in tissue degradation.Type: GrantFiled: February 3, 1999Date of Patent: September 26, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Andrew Miller, Mark Whittaker, Raymond Paul Beckett
-
Patent number: 6103739Abstract: A compound of general formula (I), wherein X is a group of formula (II) or (III), R.sub.2, R.sub.1, R.sub.21, R.sub.3, R.sub.4, and R.sub.5 being as defined in the specification are matrix metalloproteinase inhibitors.Type: GrantFiled: April 22, 1998Date of Patent: August 15, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Christopher David Floyd, Raymond Paul Beckett, Mark Whittaker, Andrew Miller
-
Patent number: 6093798Abstract: The present invention describes solid phase reaction products of a solid substrate carrying a plurality of covalently bound hydroxylamine or protected hydroxylamine groups of formula (A) or (B): ##STR1## where P.sub.1 is hydrogen or an amino protecting group, P.sub.2 is hydrogen or a hydroxyl protecting group, and the bond designated (a) covalently links the formula (A) or (B) to the residue of the solid substrate, and is cleavable under acid conditions or by photolysis. The solid phase reaction products can be used for the synthesis of hydroxamic acid derivatives or a combinatorial library of such compounds.Type: GrantFiled: June 9, 1999Date of Patent: July 25, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Christopher David Floyd, Christopher Norman Lewis
-
Patent number: 6060064Abstract: Chimeric virus-like particles produced by a non-natural particle-forming protein. The non-natural particle forming protein comprises a self-assembling particle-forming first amino acid sequence substantially homologous with a yeast retrotransposon Ty p1 protein and a second amino acid sequence. The second sequence is antigenic and is incorporated within an epitope of the first amino acid sequence, which epitope, on particles formed from the first amino-acid sequence alone, is surface exposed. Particles formed from such proteins are immunogenic and can be used in immunotherapeutic or prophylactic vaccines or as diagnostic agents.Type: GrantFiled: June 28, 1995Date of Patent: May 9, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Sally Elizabeth Adams, Nigel Robert Burns, Simon Mark Richardson
-
Patent number: 6057123Abstract: Proteinaceous molecules with stem cell inhibition activity are analogues of LD78 or MIP-1.alpha. which have mutations to prevent or reduce multimer formation beyond certain stages (for example a dodecamer). Aggregate formation is therefore inhibited, and the resulting low molecular weight monomers (or oligomers) have improved solution properties leading to enhanced productivity and greater therapeutic utility as stem cell protective agents, which are useful in tumour therapy.Type: GrantFiled: March 8, 1993Date of Patent: May 2, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Stewart Craig, Michael George Hunter, Richard Mark Edwards, Lloyd George Czaplewski, Richard James Gilbert
-
Patent number: 6022898Abstract: Compounds of general formula (II), wherein X is a hydroxamic or carboxylic acid group, Y is sulphonyl and R.sub.1 and R.sub.2 as defined in the claims are matrix metalloproteinase inhibitors.Type: GrantFiled: December 23, 1996Date of Patent: February 8, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Andrew Miller, Mark Whittaker, Raymond Paul Beckett
-
Patent number: 6022873Abstract: Compounds of formula (I) ##STR1## wherein n, V, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the specification are matrix metalloproteinase inhibitors.Type: GrantFiled: July 23, 1998Date of Patent: February 8, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Raymond Paul Beckett, Fionna Mitchell Martin, Andrew Miller, Richard Simon Todd, Mark Whittaker
-
Patent number: 6017889Abstract: Matrix metalloproteinase inhibiting compounds of formula (I), wherein X is a --CO.sub.2 H or --CONHOH group; and one of the groups proximate to the amide bonds is a steric bulky group, showing enhanced oral absorption.Type: GrantFiled: December 23, 1998Date of Patent: January 25, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Raymond Paul Beckett, Mark Whittaker, Andrew Miller
-
Patent number: 5965697Abstract: This invention relates to mutants of human RANTES (hRANTES) which, relative to the wild-type molecule, have a reduced tendency to aggregate into large multimeric complexes at physiological ionic strength and pH, and are less pro-inflammatory.Type: GrantFiled: September 25, 1997Date of Patent: October 12, 1999Assignee: British Biotech Pharmaceuticals LimitedInventors: Lloyd George Czaplewski, Michael George Hunter, Richard Mark Edwards, Keith Martyn Dawson
-
Patent number: 5962529Abstract: Compounds of general formula (II) wherein X is a hydroxamic or carboxylic acid group, Y is carbonyl or sulphonyl and R.sub.1 and R.sub.2 are as defined in the claims, are matrix metalloproteinase inhibitors.Type: GrantFiled: December 23, 1996Date of Patent: October 5, 1999Assignee: British Biotech Pharmaceuticals LimitedInventors: Andrew Miller, Mark Whittaker, Raymond Paul Beckett